Alcon to acquire STAAR Surgical

Alcon to acquire STAAR Surgical

August 05, 2025 1 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again…

Read More
Fear Of Abandonment: How To Save Our Relationships

Fear Of Abandonment: How To Save Our Relationships

I’ve had several clients who have struggled with a fear of abandonment, and as someone who’s been diagnosed with borderline personality disorder (BPD) and knows they have attachment issues, this topic seemed relevant. I hope this comprehensive article helps people overcome their fear of abandonment and loss.     What Is A Fear Of Abandonment?…

Read More
How to Get Rid of Sebaceous Filaments

How to Get Rid of Sebaceous Filaments

  Sebaceous Filaments: Understanding and Managing Them If you’ve ever looked closely at your skin, especially around your nose or on your T-zone, you might have noticed tiny, pin-like structures in your pores. These are known as sebaceous filaments, and they are a common skin concern for many. But what exactly are sebaceous filaments, and…

Read More
Easy Sweet and Sour Pork {Ready in 25!}

Easy Sweet and Sour Pork {Ready in 25!}

Sweet and Sour Pork Better than takeout? Yes! With a sticky sweet and tangy sauce, crispy pork, tender-crisp veggies and pineapple, this Sweet and Sour Pork recipe easily earns that title! Done in under 30 minutes, it’s a weeknight meal that will have everyone running to the table. Email Me the Recipe! Please enable JavaScript…

Read More
PDS Biotech Reports Final P-II (VERSATILE-002) Survival Data for PDS0101 + Keytruda in 1L HPV16+ Head & Neck Cancer

PDS Biotech Reports Final P-II (VERSATILE-002) Survival Data for PDS0101 + Keytruda in 1L HPV16+ Head & Neck Cancer

Shots: PDS Biotech reported the final topline results from the P-II (VERSATILE-002) Study evaluating safety and efficacy of PDS0101 (Versamune HPV) + Keytruda in 1L R/M HPV16+ HNSCC (n=53) In the Study PDS0101 (SC) with pembrolizumab (IV) for the first 4 cycles, then as a final single dose on cycle 12. Pembrolizumab monotx. was given…

Read More